Display options
Cite
Tchetina EV, Demidova NV, Karateev DE, et al. Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. Int J Rheumatol. 2013;2013:457876doi: 10.1155/2013/457876.
Tchetina, E. V., Demidova, N. V., Karateev, D. E., & Nasonov, E. L. (2013). Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. International journal of rheumatology, 2013457876. https://doi.org/10.1155/2013/457876
Tchetina, Elena V, et al. "Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate." International journal of rheumatology vol. 2013 (2013): 457876. doi: https://doi.org/10.1155/2013/457876
Tchetina EV, Demidova NV, Karateev DE, Nasonov EL. Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. Int J Rheumatol. 2013;2013:457876. doi: 10.1155/2013/457876. Epub 2013 Nov 14. PMID: 24348567; PMCID: PMC3848347.
Copy Download .nbib Format: NLM
Share it on

Int J Rheumatol. 2013;2013:457876. doi: 10.1155/2013/457876. Epub 2013 Nov 14.

Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate.

International journal of rheumatology

Elena V Tchetina, Natalia V Demidova, Dmitry E Karateev, Eugeny L Nasonov

Affiliations

  1. Clinical Immunology Department, Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Kashirskoye Shosse 34A, Moscow 115522, Russia.
  2. Early Rheumatoid Arthritis Department, Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow 115522, Russia.
  3. Vascular Pathology Department, Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow 115522, Russia.

PMID: 24348567 PMCID: PMC3848347 DOI: 10.1155/2013/457876

Abstract

We evaluated changes in gene expression of mTOR, p21, caspase-3, ULK1, TNF α , matrix metalloproteinase (MMP)-9, and cathepsin K in the whole blood of rheumatoid arthritic (RA) patients treated with methotrexate (MTX) in relation to their rheumatoid factor status, clinical, immunological, and radiological parameters, and therapeutic response after a 24-month follow-up. The study group consisted of 35 control subjects and 33 RA patients without previous history of MTX treatment. Gene expression was measured using real-time RT-PCR. Decreased disease activity in patients at the end of the study was associated with significant downregulation of TNF α expression. Downregulation of mTOR was observed in seronegative patients, while no significant changes in the expression of p21, ULK1, or caspase-3 were noted in any RA patients at the end of the study. The increase in erosion numbers observed in the seropositive patients at the end of the follow-up was accompanied by upregulation of MMP-9 and cathepsin K, while seronegative patients demonstrated an absence of significant changes in MMP-9 and cathepsin K expression and no increase in the erosion score. Our results suggest that increased expression of MMP-9 and cathepsin K genes in the peripheral blood might indicate higher bone tissue destruction activity in RA patients treated with methotrexate. The clinical study registration number is 0120.0810610.

References

  1. Arthritis Res Ther. 2010;12(1):R19 - PubMed
  2. Transplantation. 1994 Jun 27;57(12):1815-8 - PubMed
  3. Cytokine. 2001 Nov 21;16(4):131-42 - PubMed
  4. Arthritis Rheum. 2008 May;58(5):1293-8 - PubMed
  5. Mod Rheumatol. 2006;16(6):401-3 - PubMed
  6. Ann Rheum Dis. 2009 Jan;68(1):57-62 - PubMed
  7. Arthritis Res Ther. 2004;6(1):15-18 - PubMed
  8. Pharmacogenet Genomics. 2010 Nov;20(11):665-76 - PubMed
  9. Rheumatology (Oxford). 2001 Mar;40(3):247-55 - PubMed
  10. Arthritis Rheum. 1995 Jan;38(1):44-8 - PubMed
  11. Ann Rheum Dis. 2007 Aug;66(8):1008-14 - PubMed
  12. Rheumatol Int. 2012 Dec;32(12):3807-12 - PubMed
  13. Ann Rheum Dis. 2004 Sep;63(9):1090-5 - PubMed
  14. Ann Rheum Dis. 2002 Oct;61(10):934-6 - PubMed
  15. Lancet. 1989 May 13;1(8646):1036-8 - PubMed
  16. Arthritis Rheum. 2007 Jun;56(6):1765-75 - PubMed
  17. Rheumatology (Oxford). 2003 Aug;42(8):939-46 - PubMed
  18. Lancet. 2008 Aug 2;372(9636):375-82 - PubMed
  19. Arthritis Rheum. 2002 Apr;46(4):894-8 - PubMed
  20. Arthritis Rheum. 2004 Sep;50(9):2942-53 - PubMed
  21. J Pharmacol Exp Ther. 1993 Aug;266(2):1125-38 - PubMed
  22. Rheumatology (Oxford). 2004 May;43(5):619-25 - PubMed
  23. Clin Exp Rheumatol. 2007 Mar-Apr;25(2):231-8 - PubMed
  24. Ann Rheum Dis. 2009 Jul;68(7):1105-12 - PubMed
  25. J Rheumatol. 2010 Feb;37(2):246-56 - PubMed
  26. Rheumatol Int. 2011 Apr;31(4):543-7 - PubMed
  27. Rheumatology (Oxford). 2002 Dec;41(12):1367-74 - PubMed
  28. Ann Rheum Dis. 2007 Jan;66(1):46-52 - PubMed
  29. Arthritis Rheum. 2004 Sep;50(9):2786-93 - PubMed
  30. Genes Dev. 2004 Aug 15;18(16):1926-45 - PubMed
  31. Ann Rheum Dis. 2011 Mar;70(3):469-75 - PubMed
  32. Intern Med. 2001 Apr;40(4):275-84 - PubMed
  33. Nat Rev Mol Cell Biol. 2005 Jun;6(6):439-48 - PubMed
  34. J Rheumatol. 2003 Nov;30(11):2344-9 - PubMed
  35. Arthritis Rheum. 2002 Apr;46(4):906-12 - PubMed
  36. Clin Rheumatol. 2012 Apr;31(4):613-9 - PubMed
  37. Br J Rheumatol. 1996 Nov;35(11):1101-5 - PubMed
  38. Ann Rheum Dis. 2004 Jun;63(6):675-80 - PubMed
  39. Br J Rheumatol. 1995 Nov;34 Suppl 2:43-8 - PubMed
  40. Clin Rheumatol. 2010 Dec;29(12):1357-66 - PubMed
  41. Discov Med. 2011 Sep;12(64):229-36 - PubMed
  42. Arthritis Res Ther. 2006;8(4):R120 - PubMed
  43. Eur J Pharmacol. 2011 Nov 16;670(1):304-10 - PubMed
  44. J Biol Chem. 2005 Feb 4;280(5):3583-9 - PubMed
  45. Arthritis Rheum. 1988 Mar;31(3):315-24 - PubMed
  46. Ann Rheum Dis. 1998 Sep;57(9):533-9 - PubMed
  47. Arthritis Rheum. 2006 Mar;54(3):702-10 - PubMed
  48. J Autoimmun. 2007 Sep-Nov;29(2-3):61-8 - PubMed
  49. Clin Exp Immunol. 1996 Apr;104(1):86-91 - PubMed
  50. Rheumatology (Oxford). 2002 Jul;41(7):759-66 - PubMed
  51. Arthritis Rheum. 2006 Jan;54(1):26-37 - PubMed
  52. Arthritis Res Ther. 2009;11(1):R15 - PubMed
  53. J Am Med Assoc. 1949 Jun 25;140(8):659-62 - PubMed
  54. Rheumatol Int. 2008 May;28(7):637-41 - PubMed
  55. Ann Rheum Dis. 2003 May;62(5):423-6 - PubMed
  56. J Cell Physiol. 2004 May;199(2):244-51 - PubMed
  57. Front Biosci. 2006 Jan 01;11:529-43 - PubMed
  58. Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):715-26 - PubMed
  59. Rheumatology (Oxford). 2003 Oct;42(10):1189-96 - PubMed
  60. Arthritis Rheum. 2010 Sep;62(9):2569-81 - PubMed
  61. J Rheumatol. 2006 Feb;33(2):248-55 - PubMed
  62. J Rheumatol. 2012 Mar;39(3):470-5 - PubMed
  63. Arthritis Rheum. 2006 Jul;54(7):2047-60 - PubMed
  64. BMC Genomics. 2006 Feb 21;7:31 - PubMed
  65. Arthritis Res Ther. 2006;8(1):R28 - PubMed
  66. Ann Rheum Dis. 2004 Nov;63(11):1387-92 - PubMed
  67. Expert Opin Investig Drugs. 2009 May;18(5):585-600 - PubMed
  68. Arthritis. 2013;2013:461486 - PubMed
  69. Genes Immun. 2003 Apr;4(3):187-96 - PubMed

Publication Types